The Role of AI in Healthcare: This Week's Top Stories

AstraZeneca CEO: How AI Transforms Drug Development

Pascal Soriot, Chief Executive Officer at AstraZeneca, says artificial intelligence is helping pharmaceutical companies accelerate medicine development and improve research decision making.

"The value of AI in our industry is productivity improvement," Pascal says. "In the way you design a new medicine, a new drug, you can actually do it faster, do it smarter."

Pascal's comments come as investor concerns grow over whether large AI investments benefit the healthcare industry. He adds that AstraZeneca is already seeing applications across drug discovery and development, from identifying new targets to improving the design of potential medicines.

"You can come up with new targets, but also you can optimise your molecule [and] remove what you think are going to be potential side effects from the molecule, and AI helps you do this," Pascal says.

Albert Manzone In As Interim CEO at Perrigo

Pharmaceutical company Perrigo has announced a change in executive leadership following the departure of CEO and President Patrick Lockwood-Taylor.

The company confirmed Patrick resigned due to personal misconduct unrelated to business operations.

According to a company statement, Patrick's resignation takes effect immediately. His departure includes removal from the company board.

In the statement, Perrigo said that "certain personal conduct by Mr. Lockwood-Taylor was not consistent with the company's code of conduct and core values".

The pharmaceutical firm added that "the conduct did not involve the company's business, strategy, operations, financial reporting or results of operations".

NHS Deploys Microsoft AI to Cut Administrative Burden

NHS England will provide Microsoft 365 Copilot to 505,000 clinicians and support staff. The deployment could reduce time spent on paperwork and allow more hours for direct patient care.

According to NHS England, the technology will streamline processes, improve capacity across Trusts and reduce costs. Staff will use Copilot to create documents, analyse data and complete tasks faster.

Preet Kaur Gill, Health Innovation and Safety Minister, says: "Technology should support our NHS staff, not slow them down. Every day, doctors, nurses and other healthcare professionals spend valuable time on administrative tasks that take them away from patients."

Antibody Therapeutics: J&J Acquires Firefly Bio for US$1bn

Firefly Bio specialises in Degrader Antibody Conjugates (DACs), which combine the unique strengths of Antibody Degrader Conjugates with selective protein degraders.

Johnson & Johnson (J&J) has announced that it has entered into a definitive agreement to acquire Firefly Bio for US$1bn.

Firefly Bio’s Firelink DAC platform for KRAS-driven tumours embraces J&J's oncology pipeline and ambition to develop targeted medicines for the most prevalent and hard-to-treat solid tumours.

AMD & Imperial College London: Advancing Healthcare AI

AMD and Imperial College London have partnered to propel AI-enabled scientific discovery, establish robust sovereign AI infrastructure and develop next-generation high-performance computing (HPC) systems within the UK.

By combining AMD’s deep expertise in accelerated computing and open software with Imperial’s world-class proficiency in science, engineering and healthcare research, the two organisations intend to pioneer innovative approaches to solving some of the world's most intricate scientific problems.

"AI and accelerated computing are transforming how researchers solve complex problems and turn discoveries into real-world impact," says Dr. Lisa Su, CEO and Chair at AMD.